

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Use of an inhibitor of a receptor tyrosine kinase ligand for the manufacture of a medicament for the prevention or treatment of an at least partially therapy-resistant hyperproliferative disorder.
2. (Original) The use of claim 1 wherein the disorder is cancer.
3. (Currently Amended) The use of ~~claims 1 or 2~~ 1 wherein the disorder is an at least partially irradiation and/or medicament-resistant cancer.
4. (Currently Amended) The use of ~~any one of claims 1 to 3~~ claim 1 wherein the disorder is at least partially resistant against apoptosis-inducing therapy.
5. (Currently Amended) The use of ~~any one of claims 1 to 4~~ claim 1 wherein the disorder is at least partially resistant against administration of cytostatic and/or cytotoxic medicaments, particularly apoptosis-inducing medicaments.
6. (Currently Amended) The use of ~~any one of claims 1 to 5~~ claim 1 wherein the inhibitor of a receptor tyrosine kinase ligand is co-applied with a further therapeutic procedure and/or medicament.
7. (Original) The use of claim 6 wherein the medicament is co-applied with an irradiation therapy.
8. (Currently Amended) The use of ~~claims 6 or 7~~ 6 wherein the medicament is co-applied with a further anti-cancer medicament, particularly with a chemotherapeutic agent or with an anti-tumour antibody.

9. (Original) The use of claim 8 wherein the further anti-cancer medicament is selected from doxorubicin, a taxane, cis/trans-platin or derivatives thereof, 5-fluorouracil, mitomycin D, paclitaxel, etoposide, cyclophosphamide, docetaxel or other apoptosis-inducing drugs or proteins, in particular antibodies .
10. (Original) Use of an inhibitor of a receptor tyrosine kinase ligand for the manufacture of a medicament for increasing the efficacy of therapies against hyperproliferative disorders.
11. (Original) Use of an inhibitor of a receptor tyrosine kinase for the manufacture of a medicament for increasing the sensitivity of hyperproliferative disorders against irradiation and/or medicament treatment.
12. (Original) Use of an inhibitor of a receptor tyrosine kinase ligand for the manufacture of a medicament for the prevention or treatment of a hyperproliferative disorder which is caused by or associated with stress-induced activation of a receptor tyrosine kinase.
13. (Original) The use of claim 12, wherein the stress is an oxidative and/or osmotic stress.
14. (Currently Amended) The use of ~~claims 12 or 13~~ 12, wherein the stress is a p38-mediated stress.
15. (Currently Amended) The use of ~~claims 12 to 14~~ 12, wherein the disorder is cancer.
16. (Currently Amended) The use of ~~any one of claims 1 to 15~~ claim 1 wherein the receptor tyrosine kinase is selected from EGFR and other members of the EGFR family.

17. (Currently Amended) The use of ~~any one of claims 1 to 6~~ claim 1, wherein the receptor is EGFR.
18. (Currently Amended) The method of ~~any one of claims 1 to 17~~ claim 1 wherein the receptor tyrosine kinase ligand is a ligand binding to the extracellular domain of said receptor tyrosine kinase.
19. (Currently Amended) The use of ~~any one of claim 1 to 18~~ claim 1 wherein the receptor tyrosine kinase ligand is selected from HB-EGF, EGF, amphiregulin, betacellulin, epiregulin, TGF- α , neuregulin or heregulin.
20. (Original) The use of claim 19 wherein the receptor tyrosine kinase ligand is HB-EGF.
21. (Currently Amended) The use of ~~any one of claims 1 to 20~~ claim 1 wherein the inhibitor is an inhibitor of a metalloprotease capable of cleaving the receptor tyrosine kinase ligand or an inhibitor of regulatory steps upstream of the metalloprotease.
22. (Currently Amended) The use of ~~any one of claims 1 to 12~~ claim 1 wherein the inhibitor is a direct inhibitor of the receptor tyrosine kinase ligand.
23. (Currently Amended) The use of ~~any one of claims 1 to 22~~ claim 1 wherein the inhibitor acts on the nucleic acid level.
24. (Original) The use of claim 23 wherein the inhibitor is a specific transcription inhibitor, particularly selected from anti-sense molecules, ribozymes or RNAi molecules.
25. (Original) The use of claim 24 wherein the inhibitor is a gene inactivator.

26. (Currently Amended) The use of ~~any one of claims 1 to 22~~ claim 1 wherein the inhibitor acts on the protein level.
27. (Original) The use of claim 26 wherein the inhibitor is a specific protein inhibitor, particularly selected from antibodies or antibody fragments and/or from proteinaceous or low-molecular weight inhibitors.
28. (Original) A pharmaceutical composition or kit comprising as active ingredients
- (a) an inhibitor of a receptor tyrosine kinase ligand which is an inhibitor of a metalloprotease capable of cleaving the receptor tyrosine kinase ligand or an inhibitor of regulatory steps upstream of the metalloprotease, and
 - (b) a further medicament for the treatment of hyperproliferative disorders.
29. (Original) The composition or kit of claim 28 which additionally comprises pharmaceutically acceptable carriers, diluents and/or adjuvants.
30. (Original) A method of preventing or treating an at least partially therapy-resistant hyperproliferative disorder comprising administering an inhibitor of a receptor tyrosine kinase ligand to a subject in need thereof.